IDXX
Live chart
What they do
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis.
Grades vs sector
Momentum17th pct in sectorD
Percentile within its GICS sector across the S&P 1500.
Growth57th pct in sectorB-
Percentile within its GICS sector across the S&P 1500.
Value14th pct in sectorD-
Percentile within its GICS sector across the S&P 1500.
Profitability91st pct in sectorA
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.55 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
pricier
pricier
pricier
pricier
pricier
pricier
Forward EPS $16.74 vs trailing $14.23 (+18% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 8/9 · last two fiscal years
Altman Z-score 20.1 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $4.3B | $1.1B | $1.1B |
| 2024 | $3.9B | $887.9M | $808.1M |
| 2023 | $3.7B | $845.0M | $772.9M |
| 2022 | $3.4B | $679.1M | $394.1M |
| 2021 | $3.2B | $744.8M | $636.0M |
| 2020 | $2.7B | $581.8M | $541.1M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +8.5%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | 3.93 | 4.27 | +8.5% |
| 2026-05-05 | 3.41 | 3.47 | +1.7% |
| 2026-02-02 | 2.94 | 3.08 | +4.8% |
| 2025-11-03 | 3.15 | 3.40 | +8.1% |
| 2025-08-04 | 3.30 | 3.63 | +10.0% |
| 2025-05-01 | 2.84 | 2.96 | +4.1% |
| 2025-02-03 | 2.40 | 2.62 | +9.2% |
| 2024-10-31 | 2.69 | 2.80 | +4.3% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $1.2B | +9.7% |
| 2026-03-31 | $1.1B | – |
| 2025-12-31 | $1.1B | – |
| 2025-09-30 | $1.1B | – |
| 2025-06-30 | $1.1B | – |
Analyst actions
PT $750
PT $710
PT $670
PT $670
PT $620
Insider trades
$1.2M
–
–
Stats refreshed 2026-10-20 18:02:38 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.